In short
GIA632 is an investigational protein-based medicine being studied for atopic dermatitis and nonsegmental vitiligo. It is given as a subcutaneous injection and has no marketing authorisation. Two Phase 2 trials are registered, one suspended and one authorised, with a total of 297 planned participants.
Key points
- GIA632 is an investigational protein-based substance with no marketing authorisation.
- It is being studied in two Phase 2 trials for atopic dermatitis and nonsegmental vitiligo.
- Both trials use subcutaneous injection as the route of administration.
- The atopic dermatitis trial is suspended; the vitiligo trial is authorised.
- The vitiligo trial measures facial re-pigmentation using the F-VASI score.
- The atopic dermatitis trial measures IGA response at week 16.
What is GIA632?
GIA632 is an investigational protein-based substance being developed by Novartis Pharma AG. It has no marketing authorisation in the product records, meaning it is not yet approved as a medicine. The substance is classified under skin and connective tissue diseases as well as immune system diseases in the therapeutic area records. GIA632 has received orphan designation in two product records, which indicates it targets rare diseases. The substance appears only as the test drug in the registered trials, not as a comparator.
How does GIA632 work?
The registry records do not describe the molecular target or mechanism of action of GIA632. The substance is a protein-based product, which means it is made from or consists of proteins rather than being a small chemical molecule. No further details about how GIA632 acts in the body are available in the provided sources.
Which conditions is GIA632 being studied for?
- Atopic dermatitis — a chronic inflammatory skin condition that causes itchy, red, and dry skin. The trial studies moderate to severe forms in adults.
- Nonsegmental vitiligo — the most common type of vitiligo, where white patches appear symmetrically on both sides of the body due to loss of skin pigment. The trial focuses on facial re-pigmentation.
What do the clinical trials show?
Two Phase 2 trials are registered for GIA632. The first trial, in atopic dermatitis, has a planned enrolment of 87 participants and is currently suspended. The second trial, in nonsegmental vitiligo, has a planned enrolment of 210 participants and is authorised. Both trials are interventional and compare GIA632 against a placebo.
What are the trials measuring?
The atopic dermatitis trial measures IGA response at week 16, defined as a clear (0) or almost clear (1) score with at least a 2-point reduction from baseline. The vitiligo trial measures the percentage change from baseline to week 24 in the Facial Vitiligo Area Scoring Index (F-VASI) score, which assesses the extent of facial skin re-pigmentation.
Who can take part in these trials?
The atopic dermatitis trial enrols adult participants with moderate to severe atopic dermatitis. The vitiligo trial enrols people with nonsegmental vitiligo, the most common type. No further eligibility criteria are given in the registry records.
What side effects are known?
The registry records do not report side effects for GIA632. No supplementary sources with safety information were provided.